BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Aug. 11, 2015
View Archived Issues
Shionogi presents highlights of first quarter of fiscal 2015
Read More
Novel potent cross-reactive MAb that neutralizes influenza A virus
Read More
Novo Nordisk reviews second quarter 2015
Read More
New findings concerning the pathophysiology of spinal cord injury
Read More
Emergent BioSolutions plans to spin off immuno-oncology business
Read More
German and U.S. team presents omega-3 PUFA analogues
Read More
Allergan divulges prostanoid receptor antagonists
Read More
Piramal introduces EZH2 inhibitors
Read More
Daiichi Sankyo discloses LCAT activators
Read More
MabVax and Rockefeller University enter into research collaboration agreement
Read More
Inovio and MedImmune establish cancer vaccine collaboration
Read More
Anti-IL-23 therapy shows promise for the treatment of psoriasis
Read More
Sanofi, Evotec and Apeiron Biologics collaborate on development of immuno-oncology treatments
Read More
Phase I study investigates DNA vaccine pTVG-AR for metastatic prostate cancer
Read More
Merck & Co. divulges MGAT2 inhibitors
Read More
Cancer Research UK awards grant to Newcastle University's Northern Institute of Cancer Research
Read More
Sanofi files application for alirocumab approval in Japan
Read More
Torii and ALK's Japanese cedar pollen SLIT improves rhinitis symptoms in phase II/III trial
Read More
FDA grants orphan drug designation to recombinant IVIG-mimetic GL-2045
Read More
RegeneRx updates on clinical development of RGN-259
Read More
Antibe Therapeutics completes phase I development of ATB-346
Read More
SAGE Therapeutics and FDA agree design of phase III SAGE-547 trial under SPA
Read More
MJFF to fund preclinical study of ANAVEX 2-73 for Parkinson's disease
Read More
ProMetic Life Sciences completes first plasminogen dosing round in phase I trial
Read More
Turing acquires Daraprim U.S. rights from Impax
Read More
FDA approves Keveyis for primary hyperkalemic and hypokalemic periodic paralysis
Read More